Atlas Trials

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT02939183 · COMPLETED

Trial details

NCT number
NCT02939183
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2017-01-17
Primary completion
2022-10-06
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.